Company profile: Mesa Biotech
1.1 - Company Overview
Company description
- Provider of DNA and RNA molecular testing services and COVID-19 diagnostic products, including the Accula SARS-CoV-2 molecular test and testing kits with high-throughput and rapid tests, controls, combo kits, reagents, and buffers. Based in San Diego, California, with a satellite testing laboratory in Santa Fe, New Mexico.
Products and services
- DNA and RNA Molecular Testing Services: Mesa Biotech offers simplified nucleic-acid-based diagnostics, reducing DNA/RNA testing complexity through molecular analysis operations in San Diego and a Santa Fe satellite laboratory
- COVID Testing Kits: Mesa Biotech supplies high-throughput diagnostic assemblies to evaluate individuals for SARS‑CoV‑2, including rapid tests, controls, combo kits, reagents, and buffers
- Accula™ SARS‑CoV‑2 Test: Mesa Biotech produces a molecular diagnostic product that detects the presence of SARS‑CoV‑2 via DNA and RNA analysis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mesa Biotech
Mpex Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development of new therapies to combat antibiotic resistance, with a particular focus on gram-negative organisms. The company's internal pipeline combines proprietary formulations, PK/PD strategies and novel potentiating agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mpex Pharma company profile →
Coris BioConcept
HQ: Belgium
Website
- Description: Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coris BioConcept company profile →
Ansun BioPharma
HQ: United States
Website
- Description: Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ansun BioPharma company profile →
UrSure
HQ: United States
Website
- Description: Provider of patient-friendly diagnostic tests that measure and improve adherence to medications, initially focused on drugs that prevent and treat HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full UrSure company profile →
Taxis Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective pharmaceuticals focused on discovery and development of novel agents, including TXA709, an oral anti-MRSA agent targeting the FtsZ bacterial cell division protein (completed Phase I), and efflux pump inhibitors for Gram-negative MDR pathogens by inhibiting resistance efflux pumps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Taxis Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mesa Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mesa Biotech
2.2 - Growth funds investing in similar companies to Mesa Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mesa Biotech
4.2 - Public trading comparable groups for Mesa Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →